Article Details

Morgan Stanley Reiterates Overweight Rating for PTC Therapeutics (NASDAQ:PTCT)

Retrieved on: 2025-03-09 13:22:55

Tags for this article:

Click the tags to see associated articles and topics

Morgan Stanley Reiterates Overweight Rating for PTC Therapeutics (NASDAQ:PTCT). View article details on hiswai:

Excerpt

Morgan Stanley's price target suggests a potential upside of 33.11% from the stock's previous close. Get PTC Therapeutics alerts: Other research ...

Article found on: www.defenseworld.net

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo